AbbVie Gives Up On One Of Alector’s Alzheimer’s Candidates But Plenty More In Pipeline
Partners Still Working On Another Drug
The major has terminated its deal with Alector for a SIGLEC-3 targeting Alzheimer’s candidate but is forging ahead with another novel drug covered by the firms’ collaboration in the challenging condition.
